BeiGene (NASDAQ:BGNE) Sets New 1-Year Low at $131.50

BeiGene, Ltd. (NASDAQ:BGNE)’s stock price hit a new 52-week low during trading on Wednesday . The company traded as low as $131.50 and last traded at $131.83, with a volume of 48835 shares traded. The stock had previously closed at $134.05.

Analysts Set New Price Targets

A number of equities research analysts have commented on BGNE shares. JPMorgan Chase & Co. increased their price objective on shares of BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a report on Tuesday, March 19th. Sanford C. Bernstein reduced their target price on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a research note on Wednesday, March 27th. Guggenheim reduced their target price on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Finally, Bank of America reduced their target price on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research note on Monday, April 8th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, BeiGene has an average rating of “Moderate Buy” and a consensus price target of $251.70.

BeiGene Stock Performance

The company’s fifty day simple moving average is $155.43 and its 200 day simple moving average is $168.61. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.32 and a quick ratio of 2.09.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings data on Monday, February 26th. The company reported ($3.53) EPS for the quarter, beating the consensus estimate of ($3.61) by $0.08. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The firm had revenue of $634.40 million for the quarter, compared to the consensus estimate of $632.52 million. During the same period in the previous year, the company earned ($4.29) earnings per share. The company’s quarterly revenue was up 66.9% on a year-over-year basis. On average, analysts predict that BeiGene, Ltd. will post -8.87 earnings per share for the current fiscal year.

Insider Activity at BeiGene

In related news, CEO John Oyler sold 26,716 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total value of $3,977,745.24. Following the transaction, the chief executive officer now directly owns 12,084 shares in the company, valued at $1,799,186.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Julia Aijun Wang sold 397 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $167.08, for a total transaction of $66,330.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Oyler sold 26,716 shares of the company’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the sale, the chief executive officer now directly owns 12,084 shares of the company’s stock, valued at approximately $1,799,186.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,781 shares of company stock worth $10,222,381. Corporate insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On BeiGene

Several institutional investors and hedge funds have recently bought and sold shares of the company. LVW Advisors LLC lifted its position in BeiGene by 50.2% during the first quarter. LVW Advisors LLC now owns 1,957 shares of the company’s stock worth $306,000 after purchasing an additional 654 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of BeiGene by 175.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock worth $38,658,000 after acquiring an additional 136,458 shares during the last quarter. Virtu Financial LLC lifted its holdings in shares of BeiGene by 94.2% in the fourth quarter. Virtu Financial LLC now owns 5,319 shares of the company’s stock worth $959,000 after acquiring an additional 2,580 shares during the last quarter. Exome Asset Management LLC bought a new position in shares of BeiGene in the fourth quarter worth about $2,309,000. Finally, Virtus ETF Advisers LLC lifted its holdings in shares of BeiGene by 19.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 1,739 shares of the company’s stock worth $314,000 after acquiring an additional 280 shares during the last quarter. Institutional investors own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.